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COST-EFFECTIVENESS OF HEPATITIS A AND HEPATITIS B VACCINATION 
FOR JAIL INMATES. Aditya Sharma, Frederick L. Altice. Section of Infectious 
Diseases, Department of Internal Medicine, Yale University, School of Medicine, New 
Haven, CT.  
 
Despite evidence that viral hepatitis poses a significant risk to public health, universal 
vaccination has not yet been implemented. The risk for viral hepatitis infection is 
particularly high among injection drug users and other individuals who do not attend 
regular health care visits. Jails provide a structural opportunity to vaccinate these high 
risk individuals. HAV and HBV vaccines administered on an accelerated three week 
schedule could dramatically decrease the lifetime risk for contracting viral hepatitis 
among jail detainees. Assuming that 75% of detainees would accept vaccination, 33% 
have previous exposure to HAV, 25% have previous exposure to HBV, and independent 
future healthcare costs were US $317,000, the US health care system would save $12 per 
individual with a vaccinate upon entry program in comparison to no intervention. This 
savings translates into an economic benefit amounting to about US$ 5,000,000 saved if 
all new jail inmates in a given year were immunized. A vaccination upon entry program 
for HAV/HBV in jails should be widely implemented with coordination between the 
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Viral Hepatitis Infection in Correctional Settings 
Inmates in correctional facilities bear a disproportionately greater burden of 
infectious disease, including infection with hepatitis viruses, with estimates indicating 
that 12-39% of all Americans with hepatitis B virus or hepatitis C virus infections were 
former inmates (1). The Center for Disease Control recently reported that the current or 
previous prevalence of HBV infection among adult inmates in correctional settings 
ranges from 13% to 47%,and the prevalence of chronic HBV infection among inmates 
ranges from 1.0%--3.7%, about five times the prevalence among adults in the general 
U.S. population (2).  
Hepatitis infection outbreaks in correctional settings have unfortunately become 
common in the past 20 years. In 1985 several inmates at a municipal house of correction 
in Massachusetts were discovered to have acute onset HBV infection. Subsequent 
screening of the inmate population revealed that 43% had been exposed to HBV (3). 
Needle sharing and duration of imprisonment were determined to be the leading causes of 
transmission within the inmate population. A similar incident occurred in 2000 at a state 
correctional facility in Georgia and began when a single inmate presented with acute 
HBV infection (4). A Center for Disease Control and Prevention investigation afterwards 
revealed that 23% of inmates at the facility had markers of prior exposure to HBV. 
Among susceptible male inmates, over half reported exposure to at least one risk factor 
for HBV transmission during incarceration, which were primarily injection drug use and 




HAV outbreaks in correctional settings have been also reported (5, 6).  
Investigations of these outbreaks revealed that prisoners appear to be at greater risk for 
HAV than the general population due to high prevalence of injection drug use (7). 
Additionally, correctional settings with a rapid inmate turnover rate can serve as a 
lingering source of HAV in communities with a high level of intravenous drug use. The 
high prevalence of chronic hepatitis C among inmates indicates that HAV infection 
would likely result in poor outcomes such as hepatic failure and death (8).  
Highly effective and safe vaccines are available to prevent HAV and HBV 
transmission (2). By providing viral hepatitis prevention, in addition to ongoing harm- 
and risk- reduction counseling and substance abuse treatment to reduce risk factors of 
transmission, the personal and societal cost of hepatitis infection among inmates could be 
greatly reduced. The most significant challenge, however, is finding a prevention strategy 
that adequately meets the budgetary constraints of the health care system.  
 
Strategies for Viral Hepatitis Prevention 
Vaccination schedules have been proposed to immunize inmates for viral 
hepatitis. The typical approach is to vaccinate inmates with individual vaccines for HAV 
at a schedule of 0 and 1 month, and HBV at a schedule of 0, 1, and 6 months. Newer 
approaches utilize a combined HAV/HBV vaccine. The immunogenicity and safety of the 
combined HAV/HBV vaccine in comparison with the monovalent vaccines administered 
at the 0, 1, and 6 months schedule was first examined by a German group in 2000 (9). 
The study demonstrated that a complete three dose course of the combined vaccine on the 




immunogenicity against HAV and HBV relative to the equivalent monovalent vaccine 
course. The combined vaccination program is also likely to have a positive impact on the 
compliance rate, comfort, and cost-effectiveness due to the fewer number of injections 
for the complete course compared to individual monovalent vaccine doses. 
While this approach is appropriate in prison settings where the average length of 
stay by definition exceeds one year and ensures the vaccination schedule is completed, it 
would not be satisfactory in jail settings as most detainees would be released well before 
the sixth month (10), thereby limiting the efficacy of vaccination. The reduced time of 
incarceration in the jail setting compared to a prison setting prevents the standard 
vaccination approach with a bivalent vaccine to be successful.  
A solution to this problem would be to administer the vaccines at an accelerated 
schedule. A study in 2002 investigated the efficacy of the combined HAV/HBV vaccine 
in comparison with the monovalent vaccines on an accelerated dose schedule of 0, 7, and 
21 days in an adult population (11). The study showed that both vaccination methods 
produce the same seropositivity rate (>90%) for both anti-HAV and anti-HBs antibodies. 
Thus, bivalent vaccine or monovalent vaccines administered at an accelerated schedule 
allows immunization against HAV and HBV in less than a month, with results 
comparable to those achieved using the normal dosing schedule.  
These studies lead to two important conclusions: 1) a combined HAV/HBV 
vaccine is as effective as monovalent HAV and HBV vaccines in protecting vaccinated 
individuals against HAV and HBV infection; 2) vaccination at an accelerated schedule of 
0, 7, and 21 days results in immunogenicity comparable to vaccination at the standard 





Cost-effectiveness of Viral Hepatitis Prevention Strategies 
The cost-effectiveness of vaccination for viral hepatitis has been investigated in 
several studies. A 2001 article by the Center for Disease Control and Prevention detailed 
the cost-effectiveness of vaccinating inmates entering prisons against HBV, and how the 
cost-effectiveness is affected by factors such as the incidence and cost of disease, the rate 
of recidivism, the cost of the vaccine, the number of doses administered, and the 
prevalence of infection and intake (12). The paper also examined how economically 
desirable the program would be for the health system in general. The authors 
demonstrated the health care system, not the prisons, would be the primary beneficiary of 
a vaccination program—in 1998, the net savings would amount to about $45,000,000.  
There were several limitations to the study: 1) the assumed vaccination protocol 
was the standard 0, 1, and 6 month schedule, so jail inmates serving short sentences were 
not accounted for; 2) the model did not consider secondary transmission; 3) no 
prescreening strategy for HBV markers was considered; and 4) future unrelated health 
costs were not accounted for in the calculations of cost-effectiveness. Despite these 
limitations, the calculated benefit to the overall health system is considerable.  
Another study looked at the cost-effectiveness of pre-vaccination screening for 
HAV and HBV (13). Three different prevention protocols were considered: 1) screen and 
defer vaccination until serology results are known, 2) screen and vaccinate immediately 
to avoid a missed vaccination opportunity and modify the vaccination strategy after 
screening results are known, and 3) vaccinate without screening. In nine out of ten 




screen and begin vaccination protocol. The authors also concluded that pre-vaccination 
screening may only be effective in conditions where high immunity is likely to be 
present.   
The same group also examined the cost-effectiveness of bivalent HAV/HBV 
vaccination for prison inmates (14). This investigation determined that in settings where 
HAV prevalence rates are greater than 200%, 100%-200%, and less than 100% of the 
national average, the declines in HAV treatment costs would offset 137%, 88%, and 40% 
of the additional cost of a bivalent vaccine, respectively. Several limitations must be 
noted though: 1) the study assumed that hepatitis A rates would decline annually by 2.1% 
based on trends of past decades, 2) vaccine efficacy was based on clinical trial data, 3) 
the study did not consider that HAV vaccination would reduce work loss among former 
prisoners, and 4) the study did not assess continued HAV transmission from non-
vaccinated former prisoners to other members of society. The study is useful, however, in 
demonstrating that a bivalent vaccination program can be cost-effective in situations 
where the HAV prevalence is high.  
 
Statement of Purpose 
Inmates in correctional facilities bear a disproportionately greater burden of 
infectious disease with recent documented outbreaks of HAV and HBV (1, 4, 6, 15-17). 
Highly effective and safe vaccines are available to prevent HAV and HBV transmission 
(2). Access to prevention and medical treatment can provide lasting benefits to 




Public health officials recognize the need to include incarcerated populations in 
community-based disease prevention and control strategies. But HAV and HBV 
prevention at the jail level is particularly challenging since most inmates are detained for 
fewer than the six months required for the standard viral hepatitis immunization schedule 
(10). Administration of monovalent HAV and HBV vaccines or a combined vaccine on 
an accelerated dose schedule at 0, 7, and 21 days has demonstrated immunization rates 
equal to those realized with the standard schedule (11). This accelerated schedule would 
be particularly useful in jails since detainees could be immunized in less than a month 
despite the high rate of detainee turnover. The purpose of this investigation was to 
determine the cost-effectiveness of accelerated vaccination programs for jail detainees.  
 
Methods   
Analytic Overview 
The U.S. healthcare system is defined to be the set of health care providers and 
agencies that would manage the health needs of detainees before, during, and following 
incarceration. Inmates are assumed to be an underinsured or uninsured population and 
were assumed to be unable to afford the costs for medical treatment. For the purpose of 
this study, then, the U.S. healthcare system would bear all costs associated with vaccine 
program administration, viral hepatitis infection outcomes, as well as future independent 
healthcare costs for jail inmates.  
 
Prevalence of and risk for HAV and HBV 
History of prior viral hepatitis infection were based on studies indicating HAV 
prevalence of 33% (16) and HBV prevalence of 25% (19) on entry to jail. The lifetime 
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risk of infection with HAV and HBV for detainees was estimated by assuming a steady 
state prevalence of viral hepatitis in the general jail population. With this steady state 
assumption of viral hepatitis prevalence in the general jail population, the lifetime risk for 




The likelihood and costs of specific medical outcomes due to viral hepatitis 
infection were based on prior studies (Table 1)(12, 14). Independent future health costs 
estimated at $317,000 were added to the cost of all infection outcomes that did not lead to 
death (20). Secondary infection outcomes, defined as infection of non-incarcerated 
community members by released HAV or HBV positive detainees, were not considered. 
All infection outcomes HAV infection outcomes were separated into two 
categories: asymptomatic (22%) and symptomatic (78%). Symptomatic HAV infections 
were then divided into two categories: those requiring hospitalization (85%) and those 
not requiring hospitalization (15%). HAV infections requiring hospitalizations were 
further divided into two categories: those with infections that were fatal (2%) and those 
which were not fatal (98%).  
HBV infection outcomes were separated into two categories: asymptomatic (60%) 
and symptomatic (40%). Asymptomatic infections were divided into those that resolved 
(94%) and those which became chronic infections (6%). Chronic infections were then 
separated into two categories: those which resulted in a health carrier (85%) and those 




requiring hospitalization (12%) and those not requiring hospitalization (88%). 
Symptomatic infections requiring hospitalization were further divided into those which 
became fulminant (4%) and those that did not become fulminant (96%). Those which 
were not fulminant were further divided two categories: fulminant disease which resolved 
completely (94%) or produced chronic disease (6%). Chronic disease was then further 
separated into that which produced liver disease (15%) and that which produced a healthy 
carrier (85%). Symptomatic HBV infections requiring hospitalization due to fulminant 
disease were further divided into those which led to death (70%), those which resolved 
completely (24%), and those which produced chronic disease (6%). Chronic disease was 
again divided into two categories: that which produced liver disease (15%) and that 
which produced a healthy carrier (85%). All HBV scenarios of liver disease were divided 
into four possible outcomes: 1) chronic active hepatitis (25%), chronic persistent hepatitis 
(25%), cirrhosis (25%), and hepatocellular carcinoma (25%).  
 
Table 1. Viral hepatitis infection outcomes by percentage likelihood 
and cost 
HAV Outcomes  % Cost ($) 
Asymptomatic     22 -- 
Symptomatic     
 Not hospitalized 66.3 449 
 Hospitalized    
  Not Fatal 11.5 8121 
    Fatal   0.2 24363 
      
HBV Outcomes  % Cost ($) 
Asymptomatic      -- 
 Resolve  56.4 -- 
 Chronic    
  Healthy carrier 3.06 -- 
  Liver disease 0.54 82415 
Symptomatic     




 Hospitalized    
  Fulminant   
   Death 0.13 24363 
   Resolve 0.05 8121 
   Chronic 0.01 19265 
  Not fulminant   
   Resolve 4.33 8121 
      Chronic 0.28 19265 
 
Vaccine Immunogenecity 
Immunogenecity conferred due to  number of vaccine doses administered on the 
accelerated schedule were based on prior studies (Table 2)(13, 21, 22). The 
seroprotection rates of the bivalent vaccine were assumed to be equivalent to the 
monovalent vaccines. The monovalent HAV vaccine was estimated to confer 94% 
seroprotection against HAV at one dose, and 99% seroprotection against HAV at two 
doses. The monovalent HBV vaccine was estimated to confer 30% seroprotection against 
HBV at one dose, 77% seroprotection against HBV at two doses, and 98% seroprotection 
against HBV at three doses. The bivalent vaccine was estimated to provide 94% 
seroprotection against HAV and 30% seroprotection against HBV at one dose, 99% 
seroprotection against HAV and 77% seroprotection against HBV at two doses, and 99% 
seroprotection against HAV and 98% seroprotection against HBV at three doses. 
 
Table 2. Seroprotection rates for bivalent and monovalent 
vaccines based on doses given at the accelerated schedule 
Vaccine 1 dose 2 doses 3 doses 
HAV vaccine 0.94 0.99 0.99 





Vaccination program costs 
Costs for monovalent (Havrix: $18.50, Engerix-B: $24.25) and bivalent (Twinrix: 
$36.91) vaccines were assumed to be equivalent to the public sector cost per dose (23). 
The cost of screening was estimated solely by the cost for antibody tests for anti-HAV 
($17.31) and anti-HBs ($15.01), which were based on national Medicaid fees (24).  
 
Consent and Length of Stay 
The study assumed that 75% of inmates would accept an offer for vaccination, 
and 90% would consent to screening (25). Inmates who declined vaccination were 
assumed to have a 33% lifetime risk of infection with HAV and 25% with HBV, as per 
the steady state assumption of HAV and HBV prevalence in the population. The amount 
of time available for vaccination or screening was estimated by length of stay data: 15% 
would be released within one week, 10% in two weeks, 15% in three weeks, and 60% 
would be released after three weeks (10).  
 
Protocol for No Intervention Model 
The model accounted for the likelihood of infection with HAV, HBV, or both 
over the course of a detainee’s lifetime, and the expected medical cost of infection 
outcomes. At intake, inmates were divided into two categories: likelihood of exposure to 
HAV prior to intake (33%) and likelihood of no prior exposure to HAV (67%). Inmates 
with prior exposure to HAV were further categorized by probability of prior exposure to 
HBV (25%) and probability of no prior exposure to HBV (75%). If an inmate turned out 
to be positive for HBV under this circumstance, only HBV infection outcomes and their 
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associated costs were considered. Inmates who were positive for HAV exposure and 
negative for HBV exposure were further separated by lifetime likelihood of acquiring 
HBV (25%) and lifetime likelihood of not acquiring HBV (75%). If an HAV positive and 
HBV negative inmate were exposed to HBV following incarceration, then only HBV 
infection outcomes and associated costs were considered. If an HAV positive and HBV 
negative inmate avoided exposure to HBV following incarceration, then only HAV 
infection outcomes and associated costs were considered. 
Inmates with no prior exposure to HAV were further categorized by probability of 
prior exposure to HBV (25%) and probability of no prior exposure to HBV (75%). If an 
inmate turned out to be positive for HBV under this circumstance, only HBV infection 
outcomes and their associated costs were considered. Inmates who were negative for 
HAV exposure and negative for HBV exposure were further separated by lifetime 
likelihood of acquiring HBV (25%) and lifetime likelihood of not acquiring HBV (75%). 
If an HAV negative and HBV negative inmate were exposed to HBV following 
incarceration, then only HBV infection outcomes and associated costs were considered. If 
an HAV negative and HBV negative inmate were not exposed to HBV following 
incarceration, then those inmates were further separated by lifetime likelihood of 
exposure to HAV following incarceration (33%) and lifetime likelihood of no exposure to 
HAV following incarceration (67%). An HAV negative, HBV negative inmate who 
acquired HAV after incarceration faced HAV infection outcomes and their associated 
costs. An HAV negative and HBV negative inmate who avoided exposure to both HBV 





Protocol for Vaccinate on Entry using Monovalent Vaccines 
Inmates were assigned to three categories based on expected percentages of how 
many would stay in jail for one (15%), two (10%), or three (75%) doses of the vaccine. In 
the next step of the model, inmates were separated on whether they would accept 
vaccination (75%) or decline vaccination (25%). Inmates who accepted vaccination 
received the prearranged number of monovalent vaccine doses based on expected length 
of stay in jail. An inmate could receive a maximum of three doses of the monovalent 
HBV vaccine and two doses of the monovalent HAV vaccine.  
These inmates were then divided into two categories: likelihood of exposure to 
HAV prior to intake (33%) and likelihood of no prior exposure to HAV (67%). Inmates 
with prior exposure to HAV were further categorized by probability of prior exposure to 
HBV (25%) and probability of no prior exposure to HBV (75%). Inmates positive for 
both HAV and HBV were arranged to face only HBV infection outcomes. HAV positive 
inmates who were HBV negative were then divided into two categories: those protected 
from HBV based on number of monovalent HBV vaccine doses administered (one dose  
30%, two doses 77%, three doses 98%), and those not protected from HBV despite 
vaccination based on number of vaccine doses administered (one dose 70%, two doses 
23%, three doses 2%). Inmates who were HAV positive and protected from HBV faced 
HAV infection outcomes. HAV positive inmates who were not protected from HBV 
despite vaccination were further divided into those who would be infected with HBV 
following incarceration (25%) and those who would not be infected with HBV following 
incarceration (75%). Inmates who were HAV positive, were not protected from HBV 




to face only HBV infection outcomes. Inmates who were HAV positive, were not 
protected from HBV despite vaccination, and avoided infection by HBV following 
incarceration faced only HAV infection outcomes.  
Inmates with no prior exposure to HAV were further categorized by probability of 
prior exposure to HBV (25%) and probability of no prior exposure to HBV (75%). 
Inmates negative for HAV and positive HBV faced only HBV infection outcomes. HAV 
negative inmates who were HBV negative were then divided into two categories: those 
protected from HBV based on number of vaccine doses administered (one dose 30%, two 
doses 77%, three doses 98%), and those not protected from HBV despite vaccination 
based on number of vaccine doses administered (one dose 70%, two doses 23%, three 
doses 2%). Inmates who were HAV negative and protected from HBV were then 
categorized into two groups: those protected from HAV based on number of vaccine 
doses administered (one dose, 94%; two doses, 99%), and those not protected from HAV 
despite vaccination based on number of vaccine doses administered (one dose, 6%; two 
doses, 1%). HAV negative and HBV negative inmates who were protected against HAV 
and HBV faced future unrelated health costs. HAV negative and HBV negative inmates 
who were protected against HBV but not against HAV were further divided into those 
who would acquire HAV after incarceration (33%) and those who would avoid HAV 
infection after incarceration (67%). HAV negative and HBV negative inmates who were 
protected against HBV but not against HAV and were then exposed to HAV after 
incarceration faced HAV infection outcomes. HAV negative and HBV negative inmates 
who were protected against HBV but not against HAV and avoided HAV infection after 




inmates who were not protected against HBV despite vaccination were further divided 
into those who would acquire HBV after incarceration (25%) and those who would avoid 
HBV infection after incarceration (75%). HAV negative and HBV negative inmates who 
were not protected against HBV despite vaccination and acquired HBV after 
incarceration faced HBV infection outcomes. HAV negative and HBV negative inmates 
who were not protected against HBV despite vaccination and avoided HBV infection 
after incarceration were separated into two groups: those protected from HAV based on 
number of vaccine doses administered (one dose 94%, two doses 99%), and those not 
protected from HAV despite vaccination based on number of vaccine doses administered 
(one dose 6%, two doses 1%). HAV negative and HBV negative inmates who were not 
protected against HBV despite vaccination but avoided HBV infection after incarceration 
and were protected against HBV faced only future unrelated health costs. HAV negative 
and HBV negative inmates who were not protected against HBV despite vaccination but 
avoided HBV infection after incarceration and were not protected against HAV were 
divided into two categories: those who would acquire HAV infection after incarceration 
(33%) and those who would avoid HAV infection after incarceration (67%). HAV 
negative and HBV negative inmates who were not protected against HBV despite 
vaccination, avoided HBV infection after incarceration, were not protected against HAV 
despite vaccination, and acquired an HAV infection after incarceration faced HAV 
infection outcomes. HAV negative and HBV negative inmates who were not protected 
against HBV despite vaccination, avoided HBV infection after incarceration, were not 
protected against HAV despite vaccination, and avoided HAV infection after 





Protocol for Vaccinate on Entry using Bivalent Vaccines 
Inmates were assigned to three categories based on expected percentages of how 
many would stay in jail for one (15%), two (10%), or three (75%) doses of the vaccine. In 
the next step of the model, inmates were separated on whether they would accept 
vaccination (75%) or decline vaccination (25%). Inmates who accepted vaccination 
received the prearranged number of bivalent vaccine doses.  
These inmates were then divided into two categories: likelihood of exposure to 
HAV prior to intake (33%) and likelihood of no prior exposure to HAV (67%). Inmates 
with prior exposure to HAV were further categorized by probability of prior exposure to 
HBV (25%) and probability of no prior exposure to HBV (75%). Inmates positive for 
both HAV and HBV were arranged to face only HBV infection outcomes. HAV positive 
inmates who were HBV negative were then divided into two categories: those protected 
from HBV based on number of bivalent vaccine doses administered (one dose 30%, two 
doses 77%, three doses 98%), and those not protected from HBV despite vaccination 
based on number of bivalent vaccine doses administered (one dose 70%, two doses 23%, 
three doses 2%). Inmates who were HAV positive and protected from HBV faced HAV 
infection outcomes. HAV positive inmates who were not protected from HBV despite 
vaccination were further divided into those who would be infected with HBV following 
incarceration (25%) and those who would not be infected with HBV following 
incarceration (75%). Inmates who were HAV positive, were not protected from HBV 
despite vaccination, and were infected with HBV following incarceration were assigned 




protected from HBV despite vaccination, and avoided infection by HBV following 
incarceration were assigned to face only HAV infection outcomes.  
Inmates with no prior exposure to HAV were further categorized by probability of 
prior exposure to HBV (25%) and probability of no prior exposure to HBV (75%). 
Inmates negative for HAV and positive HBV were arranged to face only HBV infection 
outcomes. HAV negative inmates who were HBV negative were then divided into two 
categories: those protected from HBV based on number of bivalent vaccine doses 
administered (one dose 30%, two doses 77%, three doses 98%), and those not protected 
from HBV despite vaccination based on number of bivalent vaccine doses administered 
(one dose 70%, two doses 23%, three doses 2%). Inmates who were HAV negative and 
protected from HBV were then categorized into two groups: those protected from HAV 
based on number of bivalent vaccine doses administered (one dose, 94%; two doses, 
99%, three doses, 99%), and those not protected from HAV despite vaccination based on 
number of bivalent vaccine doses administered (one dose, 6%; two doses, 1%, three 
doses, 1%). HAV negative and HBV negative inmates who were protected against HAV 
and HBV faced future unrelated health costs. HAV negative and HBV negative inmates 
who were protected against HBV but not against HAV were further divided into those 
who would acquire HAV after incarceration (33%) and those who would avoid HAV 
infection after incarceration (67%). HAV negative and HBV negative inmates who were 
protected against HBV but not against HAV and were then infected with HAV after 
incarceration faced HAV infection outcomes. HAV negative and HBV negative inmates 
who were protected against HBV but not against HAV and avoided HAV infection after 




inmates who were not protected against HBV despite vaccination were further divided 
into those who would acquire HBV after incarceration (25%) and those who would avoid 
HBV infection after incarceration (75%). HAV negative and HBV negative inmates who 
were not protected against HBV despite vaccination and acquired HBV after 
incarceration faced HBV infection outcomes. HAV negative and HBV negative inmates 
who were not protected against HBV despite vaccination and avoided HBV infection 
after incarceration were separated into two groups: those protected from HAV based on 
number of bivalent vaccine doses administered (one dose, 94%; two doses, 99%, three 
doses, 99%), and those not protected from HAV despite vaccination based on number of 
bivalent vaccine doses administered (one dose, 6%; two doses, 1%, three doses, 1%). 
HAV negative and HBV negative inmates who were not protected against HBV despite 
vaccination but avoided HBV infection after incarceration and were protected against 
HBV faced only future unrelated health costs. HAV negative and HBV negative inmates 
who were not protected against HBV despite vaccination but avoided HBV infection after 
incarceration and were not protected against HAV were divided into two categories: 
those who would acquire HAV infection after incarceration (33%) and those who would 
avoid HAV infection after incarceration (67%). HAV negative and HBV negative 
inmates who were not protected against HBV despite vaccination, avoided HBV infection 
after incarceration, were not protected against HAV despite vaccination, and acquired an 
HAV infection after incarceration faced HAV infection outcomes. HAV negative and 
HBV negative inmates who were not protected against HBV despite vaccination, avoided 
HBV infection after incarceration, were not protected against HAV despite vaccination, 





Protocol for Screen and Defer Vaccination 
 This model examined the scenario in which inmates would first be screened for 
exposure to HAV and HBV, and would then be vaccinated based on the screening results. 
Inmates were first organized into two categories: those who would accept an offer to 
screen for prior HAV and HBV infection (90%) and those who would decline an offer to 
screen for prior infection (10%), with the assumption that the screening results would be 
made available after one week.  
The model then categorized inmates into those who had been exposed to HAV 
(33%) and those who had not be been exposed to HAV (67%). These inmates were 
further organized based on likelihood of prior HBV exposure (25%) and no prior HBV 
exposure (75%). Inmates who were found to be HAV positive and HBV positive based 
on screening results would not be eligible for vaccination and faced HBV infection 
outcomes. Inmates who were HAV positive and HBV negative were separated by 
likelihood of accepting vaccination (75%) and declining vaccination (25%). Inmates who 
declined vaccination were separated by likelihood of exposure to HBV after incarceration 
(25%) and no exposure to HBV after incarceration (75%). HAV positive and HBV 
negative inmates who declined vaccination and were infected with HBV after 
incarceration faced HBV infection outcomes. HAV positive and HBV negative inmates 
who declined vaccination and avoided HBV infection after incarceration faced HAV 
infection outcomes. 
HAV positive and HBV negative inmates who accepted vaccination were then 




on anticipated length of stay after results of the viral hepatitis screening were available: 
those who would receive three doses of the monovalent HBV vaccine (60%), those who 
would receive two doses of the HBV vaccine (15%), those who would receive one dose 
of the HBV vaccine (10%), and those who would be released from jail before receiving a 
single dose of the HBV vaccine (15%). The model then accounted for the likelihood of 
protection against HBV based on number of doses of the HBV vaccine administered: 
three doses (98% protected, 2% not protected); two doses (77% protected, 23% not 
protected); one dose (30% protected, 70% not protected); no dose (0% protected, 100% 
not protected). Inmates who were not protected against HBV were further divided into 
those who would acquire HBV after incarceration (25%) and those who would avoid 
HBV infection after incarceration (75%). HAV positive and HBV negative inmates who 
would be vulnerable to HBV despite vaccination and were exposed to the virus faced 
HBV infection outcomes. HAV positive and HBV negative inmates who would be 
vulnerable to HBV despite vaccination and avoided HBV infection after incarceration 
faced HAV infection outcomes only.  
Inmates who were found to be HAV negative and HBV positive would be eligible 
for the HAV vaccine and were categorized into those who would accept the HAV vaccine 
(75%) and those who would decline the HAV vaccine (25%). Inmates who declined 
vaccination faced HBV infection outcomes. Inmates who accepted the HAV vaccine 
were separated by number of doses of vaccine to be administered based on the expected 
length of stay following the report of the screening: two doses (75%), one dose (10%), 
and no dose (15%). All of these inmates, regardless of post-incarceration exposure to 




Inmates who were found to be HAV negative and HBV negative would be 
eligible for the bivalent HAV/HBV vaccine and were categorized by those who would 
accept the vaccine (75%) and those who would decline the vaccine (25%). Those who 
declined the vaccine were next divided into two categories: those who would be infected 
with HBV after incarceration (25%) and those who would avoid HBV infection after 
incarceration (75%). HAV negative and HBV negative inmates who declined vaccination 
and were exposed to HBV after incarceration faced HBV infection outcomes. HAV 
negative and HBV negative inmates who declined vaccination and avoided exposure to 
HBV after incarceration were further categorized based on likelihood of exposure to 
HAV after incarceration (33%) and no exposure to HAV after incarceration (67%). HAV 
negative and HBV negative inmates who declined vaccination and avoided exposure to 
HBV but were infected by HAV after incarceration faced HAV infection outcomes. HAV 
positive and HBV negative inmates who declined vaccination and avoided both HAV and 
HBV infection after incarceration faced only future unrelated healthcare costs. 
HAV and HBV negative inmates who declined vaccination and were exposed to 
HBV following incarceration faced HBV infection outcomes. HAV and HBV negative 
inmates who declined vaccination and avoided HBV infection following incarceration 
were then separated based on likelihood of exposure to HAV after incarceration (33%) 
and no exposure to HAV after incarceration (67%). HAV and HBV negative inmates who 
declined vaccination, avoided HBV infection after incarceration, and were infected with 
HAV after incarceration faced HAV infection outcomes; those who avoided HAV 




HAV negative and HBV negative inmates who accepted vaccination were 
separated by number of doses to be administered based on estimated length of 
incarceration following screening: three doses (60%), two doses (15%), one dose (10%), 
and no doses (15%). Inmates without previous exposure to HAV or HBV who received 
no doses of the bivalent vaccine were separated by likelihood of exposure to HBV 
following incarceration (25%) and no exposure to HBV following incarceration (75%). 
HAV and HBV negative inmates who received no vaccine doses and were exposed to 
HBV after incarceration faced HBV infection outcomes. HAV and HBV negative 
inmates who received no vaccine doses and avoided HBV infection after incarceration 
were further organized according to likelihood of exposure to HAV after incarceration 
(33%) and no exposure to HAV after incarceration (67%). HAV and HBV negative 
inmates who received no vaccine doses, avoided HBV infection but suffered an HAV 
infection after incarceration faced HAV infection outcomes. HAV and HBV negative 
inmates who received no vaccine doses and avoided exposure to both HAV and HBV 
faced only future unrelated healthcare costs.  
 HAV and HBV negative inmates who would receive vaccine doses were divided 
by the expected protection against HAV and HBV based on number of doses of the 
bivalent vaccine administered: three doses (98% protected against HBV, 2% not 
protected against HBV; 99% protected against HAV, 1% not protected against HAV), 
two doses (77% protected against HBV, 23% not protected against HBV; 99% protected 
against HAV, 1% not protected against HAV), one dose (30% protected against HBV, 
70% not protected against HBV; 94% protected against HAV, 6% not protected against 




divided into those who would acquire HBV after incarceration (25%) and those who 
would avoid HBV infection after incarceration (75%). HAV and HBV negative inmates 
who would be vulnerable to HBV despite vaccination and were exposed to the virus 
faced HBV infection outcomes. HAV and HBV negative inmates who would be 
vulnerable to HBV despite vaccination and avoided HBV infection after incarceration, 
and were vulnerable to HAV despite vaccination were further separated based on 
likelihood of exposure to HAV after incarceration (33%) and no exposure to HAV after 
incarceration (67%). HAV and HBV negative inmates vulnerable to HAV and HBV 
despite vaccination and avoided HBV infection after incarceration, but were exposed to 
HAV after incarceration faced HAV infection outcomes. HAV and HBV negative 
inmates vulnerable to HAV and HBV despite vaccination but avoided infection by both 
HAV and HBV after incarceration faced only future unrelated healthcare costs. 
 
Sensitivity Analysis 
To account for variations in estimated values for the variables in the model, 
sensitivity analysis was performed to evaluate the effect on the cost effectiveness analysis 
due to 1) prevalence of HAV and HBV exposure at intake, 2) lifetime risk of HAV and 
HBV infection, 3) HAV and HBV vaccine immunogenicity, and 4) independent future 
healthcare costs. Sensitivity analyses were performed with the SensIt plugin for 








The expected cost of each program to the U.S. healthcare system over the lifetime 
of detainees is listed in Table 3, with the estimate of 420,000 new jail detainees per year 
(26). Cost per detainee was calculated by subtracting independent future health costs 
estimated at $317,000. The vaccinate on entry programs proved to be the least expensive 
compared to no intervention and screen and defer vaccination. Screen and defer 
vaccination was more expensive than no intervention. Of the two vaccinate on entry 
programs, using a bivalent vaccine was marginally less costly than using monovalent 
vaccines. Over the lifetime of the detainees, a vaccinate on entry program using 
monovalent vaccines would save US $4,560,000 over the expected cost of \no 
intervention, while a vaccinate on entry program using bivalent vaccines would save US 
$4,970,000. A screen and defer program would cost US $1,900,000 above the expected 
cost of a no intervention program.  
 
Table 3. Expected costs of jail vaccination programs for viral hepatitis over lifetime 
of detainees 
Program Cost per detainee ($) Overall cost ($) 
No intervention 371 155,862,288 
Vaccinate on Entry with Bivalent 
Vaccines 359 150,893,173 
Vaccinate on Entry with 
Monovalent Vaccine 360 151,305,508 
Screen and Defer Vaccination 376 157,764,657 
 
Infections Averted 
 The anticipated number of viral hepatitis infections averted for each vaccination 
scenario is listed in Table 4. These results are for an expected cohort of 420,000 jail 






inmates in a given year (26) and represent viral hepatitis infections averted over the 
course of the lifetimes of the detainees within the cohort. No intervention would allow 
26,247 new HAV infections, 12,135 new HBV infections, and 66,615 new HAV/HBV 
co-infections. A vaccinate on entry program would allow 4,935 new HAV infections, 
7,630 new HBV infections, and 19,499 new HAV/HBV co-infections. A screen and defer 
vaccination program would allow 10,174 new HAV infections, 8,150 new HBV 
infections, and 30,254 new HAV/HBV co-infections. In terms of the number of 
infections averted, this translates to 21,312 HAV infections, 4,505 HBV infections, and 
47,115 HAV/HBV co-infections averted by a vaccinate on entry program; and 16,073 
HAV infections , 3,985 HBV infections, and 36,360 HAV/HBV co-infections averted by 
a screen and defer vaccination program. Both vaccination scenarios avert hepatitis 
infections, but the number averted is clearly higher in the vaccinate on entry scenario. 
Table 4. Expected Number of Infections Averted per Vaccination Scenario 
Infection Type Vaccinate on Entry Screen and Defer 
HAV 21,312 16,073 
HBV 4,505 3,985 
HAV/HBV 47,115 36,360 
 
Sensitivity Analysis 
For both vaccination scenarios, prior HAV exposure had a higher effect on cost savings 
than prior HBV exposure. Additionally, lifetime risk of infection with HAV had a greater 
effect on cost savings compared to lifetime risk of HBV infection. A vaccinate on entry 
program would also no longer generate cost savings over no intervention if at least 42% 
of inmates at intake had prior HAV exposure, or at least 36% of inmates had prior HBV 
exposure. A vaccinate on entry program also would no longer generate cost savings if the 
lifetime risk of HAV infection was less than 25%, or if the lifetime risk of infection with 
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HBV was less than 8% (Figure 1). A screen and defer vaccination program would 
generate cost savings over no intervention if at most 28% of inmates at intake had prior 
HAV exposure, or at most 16% of inmates had prior HBV exposure. A screen and defer 
vaccination program would also no longer generate cost savings over no intervention if 
the lifetime risk of HAV infection was less than 37%, or if the lifetime risk of infection 
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Figure 1. Sensitivity Analysis: Effect of Viral Hepatitis Prevalence at Intake and Lifetime Viral 
Hepatitis Infection Risk on Cost Savings Per Detainee for a Vaccinate on Entry Program. A 
vaccinate on entry program would no longer generate cost savings when HAV prevalence at intake 
exceeded 42%, or HBV prevalence exceeded 36%. The program would also generate cost savings if 
inmates’ lifetime risk of infection with HAV was greater than 25% or lifetime risk of infection with 
HBV was greater than 8%.  
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Figure 2. Sensitivity Analysis: Effect of Viral Hepatitis Prevalence at Intake and Lifetime Viral 
Hepatitis Infection Risk on Cost Savings Per Detainee for a Screen and Defer Vaccination Program. 
A screen and defer vaccination program would generate cost savings if HAV prevalence at intake did 
not exceed 28% or HBV prevalence at intake did not exceed 16%. The program would also generate 
cost savings if inmates’ lifetime risk of infection with HAV was greater than 37%, or lifetime risk of 
infection with HBV was greater than 34%. 
 
All vaccination programs decreased in cost savings as expected vaccine 
immunogenicity decreased (Figure 3). A vaccinate on entry program with the monovalent 
vaccines would no longer generate cost savings over no intervention if the conferred 
immunogenicity was 88% of the expected values. A vaccinate on entry program with the 
bivalent vaccine would no longer generate cost savings over no intervention if the 
conferred immunogenicity was 87% of the expected. A screen and defer vaccination 
program would not produce cost savings over no intervention at any reduced vaccine 
immunogenicity.  
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Figure 1. Sensitivity Analysis: Effect of 
Viral Hepatitis Prevalence at Intake on 
Cost Savings Per Detainee for a 
Vaccinate on Entry Program. A 
vaccinate on entry program would no 
longer generate cost savings when 
HAV prevalence at intake exceeded 
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Monovalent vaccination Bivalent vaccination Screen and defer vaccination  
Figure 3.  Effect of Change in Vaccine Immunogenecity on Cost Savings. A vaccinate on entry 
program would no longer generate cost savings if vaccine immunogenicity at the accelerated schedule 
was less than 88% of the standard schedule. Screen and defer vaccination would not generate cost 
savings regardless of vaccine immunogenicity.  
 
Cost savings for all vaccination programs decreased as future health care costs 
increased (Figure 4). A vaccinate on entry program would not realize cost savings if 
independent future healthcare costs exceeded US $358,000. A screen and defer 
vaccination program would not generate cost savings if independent future healthcare 
costs exceeded US $294,000. Both programs would realize greater cost savings to the 
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Vaccinate on Entry Screen and Defer Vaccination  
Figure 4. Sensitivity Analysis: Effect of Future Healthcare Costs on Vaccination Program Cost 
Savings. Increased future unrelated healthcare costs would offset the cost savings realized in a 
vaccination program.  
 
Discussion 
Not vaccinating jail inmates for HAV and HBV would cost the U.S. healthcare 
system US$ 371 per detainee over a lifetime course assuming future unrelated healthcare 
cost of US $317,000 per detainee. Screening for prior infection and deferring vaccination 
until infection history was determined would cost about US $376 per detainee. 
Vaccination for HAV and HBV with a combined vaccine on an accelerated dosing 
schedule would cost US$ 359 per detainee; immunization at an accelerated schedule with 
a maximum of three doses of HBV vaccine and two doses of HAV vaccine would cost 
US$ 360 per detainee. A vaccinate on entry program averts more HAV infections, HBV 
infections, and HAV/HBV co-infections than a screen and defer vaccination program. 
The overall healthcare system would save about US$ 12 per detainee with a vaccinate on 
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entry program with a bivalent vaccine compared to no intervention. This savings 
translates into an economic benefit amounting to about US$ 5,000,000 saved by the U.S. 
healthcare system in the long-term if such a program were implemented for all new jail 
inmates in a given year. Screen and defer vaccination did not generate cost savings.  
Both vaccinate on entry and screen and defer vaccination program would generate 
cost savings if the exposure rate of HAV or HBV at entry was lower than expected or if 
the lifetime risk of infection with either virus was higher than expected. Immunogenicity 
is a critical factor in estimating overall cost savings, as vaccinate on entry programs 
would no longer produce cost savings if conferred immunogenicity from either 
monovalent or bivalent vaccines was below 90% of the expected values. Future 
healthcare costs also proved to be important in predicting cost savings; if independent 
future healthcare costs were greater than US $358,000 a vaccinate on entry program 
would no longer generate costs savings.  
There are several important limitations to these models. First, lifetime risk of 
infection was assumed to be constant, though this risk would likely increase as detainees 
face repeated encounters with jails and prisons (27). The models also assumed a lifetime 
risk of infection equal to that of the general population, though correctional inmates 
demonstrate markedly higher amounts of risk behaviors that would increase the 
likelihood of viral transmission. Increased rates of infection due to recidivism and risky 
behaviors would in turn increase expected infection costs of non-immunized detainees, 
which would make vaccination programs more cost-effective as demonstrated in the 
sensitivity analyses. The models also did not account for other causes of poor viral 







high burden of HIV and HCV, and associated substance abuse problems compared to the 
general population (7, 28-31). Co-infection with HIV or HCV would increase rates of 
HAV and HBV morbidity (32). Liver damage secondary to substance abuse, particularly 
alcohol abuse, would also contribute to poor HAV and HBV outcomes. Co-infection and 
substance abuse would therefore increase the cost of medical complications secondary to 
HAV and HBV infection. Jail inmates may have other health concerns that would result 
in a decreased seroprotection rate compared to subjects involved in controlled vaccine 
trials. As the sensitivity analysis demonstrated, however, a vaccinate on entry program 
would realize cost savings provided that seroprotection against HAV and HBV was at 
least 40% of the expected rates. The models did not consider the broader societal risks 
averted by HAV and HBV prevention. Infected detainees could transmit HAV or HBV to 
non-infected sex partners and other close contacts. Prevention of secondary infections 
increases the cost-effectiveness of vaccination, as the U.S. healthcare system also benefits 
from infections averted in the non-incarcerated population. The model also assumed that 
the future unrelated healthcare costs of jail inmates were equal to the national average of 
US $317,000. It is likely, however, that jail inmates as a vulnerable population would 
have greater healthcare needs than the non-incarcerated poplution. Thus, future unrelated 
healthcare costs of US $317,000 per detainee may be an underestimation. The cost 
savings would not be as significant if the future unrelated healthcare costs were much 
higher than the estimated value for this study.  
Most major limitations of the study would in fact increase the expected savings of 
a vaccination program over no intervention, resulting in greater overall savings. 
Nationwide effort and guidelines should be made to implement immunization programs 









with the monovalent or combined HAV/HBV vaccines on an accelerated dosage schedule 
for jail detainees in order to realize significant savings to the healthcare system. To 
accomplish this goal, the public health and correctional systems must work 
collaboratively to develop public health interventions within jail systems.   
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A screen and defer vaccination program generate cost savings over no intervention if at 
most 28% of inmates at intake had prior HAV exposure, or at most 16% of inmates had 
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Figure 1. Sensitivity Analysis: Effect of Viral Hepatitis Prevalence at Intake on Cost Savings Per Detainee for a Vaccinate 
on Entry Program. A vaccinate on entry program would no longer generate cost savings when HAV prevalence at intake 
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Lifetime risk of infection with HAV had a greater effect on cost savings 
compared to lifetime risk of HBV infection (Figures 3 & 4). A vaccinate on entry 
program would no longer generate cost savings if the lifetime risk of HAV infection was 
less than 25%, or if the lifetime risk of infection with HBV was less than 8%. A screen 
and defer vaccination program would no longer generate cost savings over no 
intervention if the lifetime risk of HAV infection was less than 37%, or if the lifetime risk 
of infection with HBV was less than 34%. Savings for both programs increased as 
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Figure 3. Sensitivity Analysis: Effect of Viral Hepatitis Lifetime Risk of Infection on Cost Savings Per Detainee for a 
Vaccinate on Entry Program. A vaccinate on entry program would generate cost savings if inmates’ lifetime risk of 
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Figure 4. Sensitivity Analysis: Effect of Viral Hepatitis Lifetime Risk of Infection on Cost Savings Per Detainee for a Screen 
and Defer Program. A screen and defer vaccination program would generate cost savings if inmates’ lifetime risk of 
infection with HAV was greater than 37%, or lifetime risk of infection with HBV was greater than 34%.  
 
 
 
